PRIORITY, NCT03139487: A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism |
|
|
| Unknown status | 2 | 176 | RoW | Rivaroxaban, Xarelto, Dalteparin, Fragmin, apixaban, eliquis | Asan Medical Center | Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma, Pancreatic Cancer, Duodenal Cancer, Esophagogastric Junction Cancer, Malignant Gastrointestinal Stromal Tumor, Ampulla of Vater Cancer, Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) | 09/21 | 09/21 | | |
